Sandoz shares dipped on their market debut on Wednesday after the generic and biosimilar drugmaker was valued at a lower-than-expected 10.3 billion Swiss francs ($11.2 billion) in its spin-off ...

Novartis’ Sandoz spinoff is right around the corner, and to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme.

Novartis' soon-to-be spun off generics division Sandoz is betting on biosimilars, copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer, to fuel its future as ...

Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority. Click here to see why NVS stock is a Hold.

Sandoz noted that generics and biosimilars account for an estimated 80% of medicines used worldwide by volume, at about 25% of the total cost.

Both Novartis and Sandoz released their latest financial reports Tuesday morning, marking the first quarterly earnings produced since the long-awaited spinoff was completed earlier this month. As part ...

Earlier on August 25, 2022, Novartis revealed its intention to separate Sandoz, the generics and biosimilars division, into an independent publicly traded company through a 100% spin-off.

Novartis' (NYSE: NVS) unit Sandoz signed an agreement with Evotec's (NASDAQ: EVO) Seattle-based subsidiary Just - Evotec Biologics for developing and manufacturing multiple biosimilars.

Following the recently announced shareholder support for the Sandoz spin-off, we expect Novartis to divest the unit in early October, likely by Oct. 4. We estimate the Sandoz generic drug business ...

Novartis AG NVS said the planned spin-off of its Sandoz unit is expected to occur on October 4, ending an era for the Swiss pharmaceutical giant in which generic and prescription drugs businesses ...